Objectives Patients treated with oral chemotherapy appear to have less contact with the treating providers. As a result, safety, adherence, medication therapy monitoring, and timely follow-up may be compromised. The trend of treating cancer with oral chemotherapy agents is on the rise. However, standard clinical guidance is still lacking for prescribing, monitoring, patient education, and follow-up of patients on oral chemotherapy across the healthcare settings. The purpose of this project is to establish an oral chemotherapy monitoring clinic, to create drug and lab specific provider order sets for prescribing and lab monitoring, and ultimately to ensure safe and effective treatment of the veterans we serve. Methods A collaborative agreement was reached among oncology pharmacists, a pharmacy resident, two oncologists, and a physician assistant to establish a pharmacist-managed oral chemotherapy monitoring clinic at the VA Sierra Nevada Healthcare System. Drug-specific electronic order sets for prescribing and lab monitoring were created for initiating new drug therapy and prescription renewal. The order sets were created to be provider-centric, minimizing clicks needed to order necessary medications and lab monitoring. A standard progress note template was developed for documenting interventions made by the clinic. Patients new to an oral chemotherapy regimen were first counseled by an oncology pharmacist. The patients were then enrolled into the oral chemotherapy monitoring clinic for subsequent follow up and pharmacist interventions. Further, patients lacking monitoring or missing provider appointments were captured through a Clinical Dashboard developed by the US Department of Veterans Affairs (VA) Regional Office (VISN21) using SQL Server Reporting Services. Between September 2014 and April 2015, a total of 68 patients on different oral chemotherapy agents were enrolled into the clinic. Results Out of the 68 patients enrolled into the oral chemotherapy monitoring clinic, 31 patients (45%) were identified as having a therapy-related problem with their oral chemotherapy regimen on a gross measure for safety and appropriateness of medication management during the course of eight months follow-up between September 2014 and April 2015. In addition, the clinic helped to reestablish care for three patients (4.4%) who were lost to follow-up. The clinic identified 12 patients (17.6%) non-adherent to their prescribed regimen in some degree, where patients were suspected to miss doses due to delay in refilling prescriptions at least three days later than the expected date. However, these patients denied non-adherence. Among them, six patients (8.8%) were truly non-adherent. These patients stated that they had missed at least one day of therapy or were not taking the medication as prescribed. Medication regimen errors were discovered for five patients, accounting for a 7.3% medication-related error rate. Finally, seven patients (10.3%) were found to have an adverse reaction attributed to their oral chemotherapy. Two of ...

The results suggest that CPS could be effectively utilized in drug therapy management of HCV-infected patients treated with DAAs.

No abstract

Docetaxel has been approved by the Food and Drug Administration for the treatment of many cancer types, including breast cancer, head and neck cancer, lung cancer, and prostate cancer. Many severe to life-threatening side effects (Grades 3-5) of docetaxel have been reported in clinical trials, case reports, and Food and Drug Administration Adverse Events Reporting System. These include anaphylactic reactions, febrile neutropenia, fluid retention, acute respiratory distress, pleural effusion, pneumonia, and peripheral neuropathy. There were fewer cardiac toxicities reported for docetaxel as compared to paclitaxel, which were less severe. In this report, we present a clinical case of docetaxel-induced cardiac-respiratory arrest in a 62-year-old Hispanic male patient with stable chronic atrial fibrillation, who has been recently diagnosed with metastatic prostate cancer. The cardiac event developed within 15 min of docetaxel infusion during the second cycle of chemotherapy despite using recommended premedication with corticosteroids.

Purpose: In radiotherapy treatments of breast patients, respirations may introduce uncertainties in target and heart locations. This study is to investigate the dosimetric impacts of these uncertainties in breast radiation treatments. Method and Materials: A 4D CT scan and a conventional helical CT scan set were acquired on each of 7 left breast patients and 5 right breast patients. Using the helical CT scan, a conventional 3D conformal plan, consisting of two tangential beams, was generated per physician's evaluation and decision. The 4D CT scan set was divided into 10 phases over the respiratory cycle. On each phase, treatment target and heart were contoured. Dose distributions were generated using the same beams as in the conventional plan. Software was developed to compute the cumulative dose distribution (4D doses) from all the phases. This 4D CT image based cumulative dose distribution would be closer to that in reality with motions taken into account. Various dosimetric parameters were obtained for treatment target and heart from the conventional plan and from the 4D cumulative dose distributions and compared to deduce the motion induced dosimetric impacts in breast radiation treatments. Studies were performed for both whole and partial breast treatments. Results: For whole breast treatment, the motion induced changes in D95, Dmax, and Dmin of PTV were 0.88% ± 20%, −0.28 ± 0.65%, and −10.17% ± 47%, respectively. For left breast, the motion induced Dmax change in heart was 22% ± 48%. For partial breast treatments, the motion induced changes in V90 and Dmin of CTV were 1.6% ± 2.7% and 3% ± 4%, respectively. Conclusions: Breathing motion may cause cold spots in the whole breast treatment, and may compromise treatment quality for some patients. It may also increase heart maximum dose. However, for the partial breast treatment, the motion impact may be insignificant with properly selected margin size. Supported in part by Varian Medical Systems.